• Sherica Celine
    Sherica Celine
    • 7 months ago
    • Practical Guidance Journal
    • pa

    Chevron Deference Reversal: FDA Rulemaking and Legal Challenges After Loper Bright

    By: Chad A. Landmon and Suzanne E. Bassett , POLSINELLI PC THIS ARTICLE PROVIDES GUIDANCE ON THE IMPACT of the U.S. Supreme Court’s recent decisions in Loper Bright 1 and Corner Post 2 on decision-making by the U.S. Food and Drug Administration...
  • Sherica Celine
    Sherica Celine
    • over 1 year ago
    • Practical Guidance Journal
    • pa

    Generative Artificial Intelligence, Data Minimization, and Today’s Gold Rush

    By: D. Reed Freeman Jr., ARENTFOX SCHIFF LLP THIS ARTICLE DISCUSSES THE PRINCIPLE OF DATA MINIMIZATION in the context of commercial applications of generative artificial intelligence (GenAI) technology and tools. In the United States, the principle...
  • Vinayak Kohli
    Vinayak Kohli
    • over 9 years ago
    • Practical Guidance Journal
    • pa

    Challenges of Taxing the Sharing Economy

    By: Jessica L. Kerner IN 2007, A HOTEL ROOM SHORTAGE IN SAN FRANCISCO prompted two roommates to create a website to rent out air mattresses in their apartment. Less than eight years later, the company they founded, Airbnb, has been valued at more than...
  • Vinayak Kohli
    Vinayak Kohli
    • over 4 years ago
    • Practical Guidance Journal
    • pa

    Force Majeure and Coronavirus (COVID-19): Seven Critical Lessons from the Case Law

    By: Timothy Murray , Murray, Hogue & Lannis There is a veritable pandemic raging, and I’m not referring to COVID-19. It’s a pandemic of webinars and legal articles about force majeure and COVID-19. Sadly, no lawyer is immune from it...
  • Vinayak Kohli
    Vinayak Kohli
    • over 4 years ago
    • Practical Guidance Journal
    • pa

    Avoiding False Claims Act Risks Relating to Federal Funding for Coronavirus (COVID-19) Relief

    By: Matthew D. Jenkins , Hunton Andrews Kurth LLP This article provides an overview of compliance obligations and federal False Claims Act (FCA) risks to healthcare and life sciences companies arising out of three funding streams made available in response...
<>